Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia

Nisreen M El-Abiad; Shelley Clifton; Samya Z Nasr

doi:10.1016/j.rmed.2007.05.014

Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia

Respir Med. 2007 Oct;101(10):2224-6. doi: 10.1016/j.rmed.2007.05.014. Epub 2007 Jun 29.

Authors

Nisreen M El-Abiad¹, Shelley Clifton, Samya Z Nasr

Affiliation

¹ Faculty of Medicine, Cairo University, Children's Hospital, Cairo, Egypt.

PMID: 17601719
DOI: 10.1016/j.rmed.2007.05.014

Abstract

Primary ciliary dyskinesia (PCD) is characterized by ultra-structural defects of the cilia. In this report, we describe the long-term use of nebulized dornase alfa in two siblings with PCD. This is the first report of long-term use of dornase alfa in PCD.

Publication types

Case Reports

MeSH terms

Adolescent
Deoxyribonuclease I / administration & dosage*
Forced Expiratory Volume / drug effects
Humans
Kartagener Syndrome / drug therapy*
Long-Term Care / methods
Male
Nebulizers and Vaporizers
Treatment Outcome

Substances

DNASE1 protein, human
Deoxyribonuclease I